CC
CMPX icon

Caxton Corporation’s Compass Therapeutics CMPX Stock Holding History

Caxton Corporation’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,495
Closed -$158K – 8
2025
Q4 		$158K Sell
29,495
-24,008
-45% -$111K 3.7% 6
2025
Q3 		$187K Buy
53,503
+10,038
+23% +$31.7K 0.82% 6
2025
Q2 		$113K Hold
43,465
– – 1.15% 6
2025
Q1 		$82.6K Hold
43,465
– – 1.63% 6
2024
Q4 		$63K Hold
43,465
– – 0.38% 10
2024
Q3 		$80K Hold
43,465
– – 0.33% 10
2024
Q2 		$43.5K Hold
43,465
– – 0.22% 10
2024
Q1 		$86.1K Hold
43,465
– – 0.49% 10
2023
Q4 		$67.8K Sell
43,465
-43,308
-50% -$74.9K 0.37% 11
2023
Q3 		$171K Buy
86,773
+43,307
+100% +$107K 0.65% 6
2023
Q2 		$138K Sell
43,466
-168,274
-79% -$528K 0.4% 5
2023
Q1 		$675K Buy
211,740
+581
+0.3% +$2.28K 1.71% 9
2022
Q4 		$1.06M Buy
+211,159
New +$842K 2.71% 10

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caxton Corporation's CMPX Position: Q1 2026 in Review

Caxton Corporation sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 29,495 shares — an estimated $158K sold.

Caxton Corporation first reported a position in CMPX in Q4 2022 and held it in 13 quarters. The position peaked at $1.06M in Q4 2022. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Caxton Corporation reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caxton Corporation sold 29,495 Compass Therapeutics shares in Q1 2026, an estimated $158K.
  • Caxton Corporation first reported a position in Compass Therapeutics in Q4 2022 and held it in 13 quarters.
  • Caxton Corporation's Compass Therapeutics position peaked at $1.06M in Q4 2022.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.